Protein kinase C overactivity impairs prefrontal cortical regulation of working memory

Science

Volumn 306, Issue 5697, 2004, Pages 882-884

  Birnbaum, S G ^a,b   Yuan, P X ^c   Wang, M ^a   Vijayraghavan, S ^a   Bloom, A K ^a   Davis, D J ^a   Gobeske, K T ^a   Sweatt, J D ^b   Manji, H K ^c   Arnsten, A F T ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN; COGNITIVE SYSTEMS; DATA REDUCTION; ELECTROPHYSIOLOGY; KNOWLEDGE REPRESENTATION; SIGNALING; STRESSES;

DISTRACTIBILITY; EMOTIONS; INTRACELLULAR SIGNALING; PROTEIN KINASE C (PKC);

ENZYMES;

CHELERYTHRINE; LITHIUM; PROTEIN KINASE C; VALPROIC ACID;

BIOLOGY;

ARTICLE; BEHAVIOR; BRAIN DYSFUNCTION; COGNITION; DISTRACTIBILITY; ELECTROPHYSIOLOGY; ENZYME ACTIVATION; ENZYME ACTIVITY; IMPULSIVENESS; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; STRESS; THOUGHT DISORDER; WORKING MEMORY;

ADRENERGIC ALPHA-AGONISTS; ALKALOIDS; ANIMALS; BENZOPHENANTHRIDINES; CARBOLINES; ELECTROPHYSIOLOGY; ENZYME ACTIVATION; FEMALE; IMIDAZOLES; LITHIUM CARBONATE; MACACA MULATTA; MALE; MEMORY; NEURONS; PHENANTHRIDINES; PREFRONTAL CORTEX; PROTEIN KINASE C; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-1; SIGNAL TRANSDUCTION; STRESS; TETRADECANOYLPHORBOL ACETATE; VALPROIC ACID;

EID: 7444256727     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.1100021     Document Type: Article

References (20)

1. P. S. Goldman-Rakic, in Psychopathology and the Brain, B. J. Carroll, J. E. Barrett, Eds. (Raven, New York, 1991), pp. 1-23.
2. C. Frith, Philos. Trans. R. Soc. London 351, 1505 (1996).
3. S. M. Lawrie et al., Biol. Psychiatry 51, 1008 (2002).
4. H. P. Blumberg et al., Am. J. Psychiatry 156, 1986 (1999).
5. A. Ellicott et al., Am. J. Psychiatry 147, 1194 (1990).
6. C. M. Mazure, Ed., Does Stress Cause Psychiatric Illness? (American Psychiatric Press, Washington, DC, 1995), vol. 46.
7. H. K. Manji, R. H. Lenox, Biol. Psychiatry 46, 1328 (1999).
8. K. Mirnics, F. A. Middleton, C. D. Stanwood, D. A. Lewis, P. Levitt, Mol. Psychiatry 6, 293 (2001).
9. P. O. Koh, C. Bergson, A. S. Undie, P. S. Goldman-Rakic, M. S. Lidow, Arch. Gen. Psychiatry 60, 311 (2003).
10. Additional background and materials and methods are available as supporting material on Science Online.
11. N. A. Sharkey, K. L. Leach, P. M. Blumberg, Proc. Natl. Acad. Sci. U.S.A. 81, 607 (1984).
12. S. C. Birnbaum, K. T. Gobeske, J. Auerbach, J. R. Taylor, A. F. T. Arnsten, Biol. Psychiatry 46, 1266 (1999).
13. A. F. T. Arnsten, R. Mathew, R. Ubriani, J. R. Taylor, B.-M. Li, Biol. Psychiatry 45, 26 (1999).
14. Z.-M. Mao, A. F. T. Arnsten, B.-M. Li, Biol. Psychiatry 46, 1259 (1999).
15. A. F. T. Arnsten, J. D. Jentsch, Pharmacol. Biochem. Behav. 58, 55 (1997).
16. A. F. T. Arnsten, Science 280, 1711 (1998).
17. J. T. Coyle, H. K. Manji, Nature Med. 8, 557 (2002).
18. J. Marcovac, C. Goldstein, Nature 334, 71 (1988).
19. H. V. Krowchuk, Annu. Rev. Nurs. Res. 13, 87 (1995).
20. We thank L. Ciavarella, T. Sadlon, and S. Johnson for their technical expertise. The cognitive and electrophysiological studies were supported by PHS MERIT Award AG06036, PHS P50 MH068789, and a grant from the Stanley Foundation to A.F.T.A. The biochemical data were supported by grants from the NIMH Intramural Program, Stanley Medical Research Institute, and National Alliance for Research on Schizophrenia and Depression to H.K.M. A.F.T.A. has received an honorarium and research contract funds (July 2004) from Marinus Pharmaceuticals, which has licensed the use of chelerythrine for treatment of cognitive function from Yale University.